Paul DePietro

Paul DePietro

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2024 in Cancer and Metastasis Reviews
Verified
Journal Article
Open access
PDF file
BTBicky Thapa
Bicky Thapa
SKShumei Kato
Shumei Kato
DNDaisuke Nishizaki
Daisuke Nishizaki
HMHirotaka Miyashita
Hirotaka Miyashita
SLSuzanna Lee
Suzanna Lee
RKRazelle Kurzrock
Razelle Kurzrock
Immune checkpoint inhibitors have changed the treatment landscape for various malignancies; however, their benefit is limited to a subset of patients. The immune machinery includes both mediators of suppression/immune evasion, such as PD-1, PD-L1, CTLA-4, and LAG-3, all of which can be inhibited by specific antibodies, and immune-stimulatory molecules, such as T-cell co-stimulatory receptors that belong to the tumor necrosis factor receptor superfamily (TNFRSF), including OX40 receptor (CD134; TNFRSF4), 4-1BB (CD137; TNFRSF9), and glucocorticoid-induced TNFR-related (GITR) protein (CD357; TNFRSF18). In particular, OX40 and its binding ligand OX40L (CD134L; TNFSF4; CD252) are critical for immunoregulation. When OX40 on activated T cells binds OX40L on antigen-presenting cells, T-cell activation and immune stimulation are initiated via enhanced T-cell survival, proliferation and cytotoxicity, memory T-cell formation, and abrogation of regulatory T cell (Treg) immunosuppressive functions. OX40 agonists are in clinical trials both as monotherapy and in combination with other immunotherapy agents, in particular specific checkpoint inhibitors, for cancer treatment. To date, however, only a minority of patients respond. Transcriptomic profiling reveals that OX40 and OX40L expression vary between and within tumor types, and that only ~ 17% of cancer patients have high OX40 and low OX40L, one of the expression patterns that might be theoretically amenable to OX40 agonist enhancement. Taken together, the data suggest that the OX40/OX40L machinery is a critical part of the immune stimulatory system and that understanding endogenous expression patterns of these molecules and co-existing checkpoints merits further investigation in the context of a precision immunotherapy strategy for cancer therapy.

29 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MNMary K Nesline
Mary K Nesline
RPRebecca A. Previs
Rebecca A. Previs
GDGrace K. Dy
Grace K. Dy
LDLei Deng
Lei Deng
YLYong Hee Lee
Yong Hee Lee
JCJeffrey Conroy
Jeffrey Conroy
Programmed cell death ligand (PD-L1) expression by immunohistochemistry (IHC) lacks sensitivity for pembrolizumab immunotherapy selection in non-small cell lung cancer (NSCLC), particularly for tumors with low expression. We retrospectively evaluated transcriptomic PD-L1 by mRNA next-generation sequencing (RNA-seq). In an unselected NSCLC patient cohort (n = 3168) tested during standard care (2017–2021), PD-L1 IHC and RNA-seq demonstrated moderate concordance, with 80% agreement overall. Most discordant cases were either low or negative for PD-L1 expression by IHC but high by RNA-seq. RNA-seq accurately discriminated PD-L1 IHC high from low tumors by receiver operator curve (ROC) analysis but could not distinguish PD-L1 IHC low from negative tumors. In a separate pembrolizumab monotherapy cohort (n = 102), NSCLC tumors classified as PD-L1 high versus not high by RNA-seq had significantly improved response, progression-free survival, and overall survival as an individual measure and in combination with IHC high or low status. PD-L1 IHC status (high or low) trended toward but had no significant associations with improved outcomes. Conventional PD-L1 IHC testing has inherent limitations, making it an imperfect reference standard for evaluating novel testing technologies. RNA-seq offers an objective PD-L1 measure that could represent a complementary method to IHC to improve NSCLC patient selection for immunotherapy.

24 August 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
JJJessica Jou
Jessica Jou
SKShumei Kato
Shumei Kato
HMHirotaka Miyashita
Hirotaka Miyashita
TKThangathurai Kartheeswaran
Thangathurai Kartheeswaran
SPSarabjot Pabla
Sarabjot Pabla
RKRazelle Kurzrock
Razelle Kurzrock
Our objective was to characterize cancer-immunity marker expression in gynecologic cancers and compare immune landscapes between gynecologic tumor subtypes and with nongynecologic solid tumors. RNA expression levels of 51 cancer-immunity markers were analyzed in patients with gynecologic cancers versus nongynecologic cancers, and normalized to a reference population of 735 control cancers, ranked from 0 to 100, and categorized as low (0–24), moderate (25–74), or high (75–100) percentile rank. Of the 72 patients studied, 43 (60%) had ovarian, 24 (33%) uterine, and 5 (7%) cervical cancer. No two immune profiles were identical according to expression rank (0–100) or rank level (low, moderate, or high). Patients with cervical cancer had significantly higher expression level ranks of immune activating, proinflammatory, tumor-infiltrating lymphocyte markers, and checkpoints than patients with uterine or ovarian cancer (P < 0.001 for all comparisons). However, there were no significant differences in immune marker expression between uterine and ovarian cancers. Tumors with PD-L1 tumor proportional score (TPS) ≥1% versus 0% had significantly higher expression levels of proinflammatory markers (58 vs. 49%, P = 0.0004). Compared to patients with nongynecologic cancers, more patients with gynecologic cancers express high levels of IDO-1 (44 vs. 13%, P < 0.001), LAG3 (35 vs. 21%, P = 0.008), and IL10 (31 vs. 15%, P = 0.002.) Patients with gynecologic cancers have complex and heterogeneous immune landscapes that are distinct from patient to patient and from other solid tumors. High levels of IDO1 and LAG3 suggest that clinical trials with IDO1 inhibitors or LAG3 inhibitors, respectively, may be warranted in gynecologic cancers.

1 August 2025 in JCO Precision Oncology
Verified
Journal Article
Open access
DNDaisuke Nishizaki
Daisuke Nishizaki
SCSharon Choi
Sharon Choi
CPChinmayi Pandya
Chinmayi Pandya
SLSuzanna Lee
Suzanna Lee
SPSarabjot Pabla
Sarabjot Pabla
SKShumei Kato
Shumei Kato
PURPOSE: Cotargetable immune pathways for available immune checkpoint inhibitors (ICIs) may mediate response and mitigate resistance. Immune profiling may provide insights into potential immunotherapy combinations and guide ongoing clinical trials. This study investigated the transcriptomic expression and clinical implications of B- and T-lymphocyte attenuator (BTLA), a promising immune target. METHODS: Altogether, 514 advanced/metastatic samples (pan-solid cancers) were analyzed using RNA sequencing. Transcriptomic expression was normalized to a reference population of 735 tumors and expressed as percentiles. BTLA, BTLA-related markers (herpes virus entry mediator [HVEM], CD160, LIGHT), and currently targetable immune pathway checkpoints (PD-1, PD-L1, PD-L2, cytotoxic T-cell lymphocyte-4 [CTLA-4], lymphocyte-activation gene 3) as well as clinical outcomes were evaluated. RESULTS: High BTLA RNA expression (≥75th percentile) was observed in 19% of tumors (96 of 514). Approximately half of these patients (44 of 96) exhibited higher coexpression (RNA) of targetable checkpoints (cluster analysis). High BTLA expression was independently associated with elevated PD-1, CTLA-4, HVEM, and CD160 RNA levels and with a breast cancer diagnosis. Outcome analysis (Kaplan-Meier) indicated that high BTLA expression correlated with significantly longer survival among ICI recipients in univariable analysis, with a trend in multivariable Cox regression (adjusted hazard ratio, 0.43 [95% CI, 0.17 to 1.08], P = .07). Notably, expression patterns of BTLA, other immune checkpoints, and BTLA-interacting molecules (HVEM, CD160, LIGHT) varied from patient to patient. CONCLUSION: High BTLA transcript expression correlates with high transcript levels of PD-1 and CTLA-4 and with high levels of its ligand HVEM. These findings might support combining anti–PD-1 or anti–CTLA-4 therapy with anti-BTLA. BTLA expression varied across cancers and showed diverse coexpression patterns with other immune markers, suggesting that individual immunomic analysis is needed as part of a precision immunotherapy approach to understanding response and resistance.

1 January 2026 in JCO Oncology Advances
Verified
Journal Article
Closed access
APAnannya Patwari
Anannya Patwari
DNDaisuke Nishizaki
Daisuke Nishizaki
TJTaylor Jensen
Taylor Jensen
PDPaul DePietro
Paul DePietro
SPSarabjot Pabla
Sarabjot Pabla
RKRazelle Kurzrock
Razelle Kurzrock
PURPOSE: PD-L1 and PD-L2 are inhibitory ligands that interact with PD-1 receptors, enabling immune escape. Although PD-L1 has been extensively studied, much less is known about PD-L2. PD-L2 expression could lead to incomplete blockade of the PD-1 axis by anti–PD-L1 agents and also influence the activity of anti–PD-1 agents. METHODS: We analyzed PD-L2 transcriptomic expression in a pan-cancer cohort (N = 514; 489 patients with advanced/metastatic disease and clinical correlates available) for associations with immunomodulatory variables and outcome. RESULTS: The most common tumors were colorectal (27% [140 of 514]), pancreatic (11% [55 of 514]), and breast cancer (9.5% [49 of 514]). High PD-L2 expression (≥75th RNA percentile rank) occurred in 19.5% (100 of 514) of patients; PD-L2 expression varied across and within tumor types. High PD-L2 independently/significantly correlated with high PD-L1, PD-1, CD4, and T-cell immunoglobulin and mucin-containing protein 3 (TIM-3) RNA levels (both as dichotomized and linear variables), high tumor mutational burden (TMB; ≥10 mutations/Mb), and a breast cancer diagnosis. In 217 patients who received immune checkpoint blockade (mainly anti–PD-1-based regimens), high versus moderate/low PD-L2 predicted longer overall survival (OS) (but not progression-free survival) in univariate analysis (median, 1.88 years [95% CI, 1.37 to not estimable] versus 1.21 years [95% CI, 0.95 to 1.54]; P = .02). In 272 patients who never received immunotherapy, high PD-L2 expression was not prognostic for OS. CONCLUSION: High PD-L2 transcripts were more common in breast cancer and associated with high expression of other immune-relevant factors: PD-L1, PD-1, CD4, and TIM-3, and with TMB ≥10 mutations/Mb. High PD-L2 levels correlated with longer OS in immunotherapy-treated patients.

Verified
Journal Article
Open access
PDF file
ASAditya Shreenivas
Aditya Shreenivas
DNDaisuke Nishizaki
Daisuke Nishizaki
SLSuzanna Lee
Suzanna Lee
SPSarabjot Pabla
Sarabjot Pabla
MNMary K Nesline
Mary K Nesline
RKRazelle Kurzrock
Razelle Kurzrock
ADORA2A (adenosine A2a receptor) and ADORA2B propagate immunoregulatory signals, including restricting both innate and adaptive immunity, though recent data also suggest a tumor suppressor effect in certain settings. We evaluated the RNA expression from 514 tumors in a clinical-grade laboratory; 489 patients with advanced/metastatic disease had clinical outcome correlates. Transcript expression was standardized to internal housekeeping genes and ranked (0–100 scale) relative to 735 specimens from 35 different cancer types. Transcript abundance rank values were defined as “low/moderate” (0–74) or “high” (75–100) percentile RNA expression ranks. Overall, 20.8% of tumors had high ADORA2A (≥75 percentile RNA rank). The greatest proportion of high ADORA2A expressors was found in neuroendocrine and breast cancers and sarcomas, whereas the lowest was found in colorectal and ovarian cancers, albeit with patient-to-patient variability. In multivariable logistic regression analysis, there was a significant positive correlation between high ADORA2A RNA expression and a high expression of the immune checkpoint-related molecules PD-1 (p = 0.015), VISTA (p ≤ 0.001), CD38 (p = 0.031), and CD39 (p ≤ 0.001). In 217 immunotherapy-treated patients, high ADORA2A did not correlate significantly with progression-free (p = 0.51) or overall survival (OS) (p = 0.09) from the initiation of the checkpoint blockade. However, high versus not-high ADORA2A transcript expression correlated with longer OS from the time of advanced/metastatic disease (N = 489 patients; (HR 0.69 (95% CI 0.51–0.95) (p = 0.02)). Therefore, high ADORA2A transcript levels may be a favorable prognostic factor, unrelated to immunotherapy. Importantly, ascertaining co-expression patterns of ADORA2A with PD-1 and VISTA in individual tumors as a basis for the precision co-targeting of ADORA2A and these other checkpoint-related molecules warrants investigation in clinical trials.